title: Targeting Ras Activity Prevented Amyloid Beta-Induced Aberrant Neuronal Cell Cycle Re-Entry and Death.
abstract: Several studies suggest that soluble Amyloid β (Aβ) oligomer-induced aberrant neuronal cell cycle re-entry is the initial trigger for a significant part of the neuronal degeneration and loss in Alzheimer's disease (AD). In this study, we investigated the role of Ras, which is a well-known protooncoprotein, in soluble Aβ oligomer-induced aberrant neuronal cell cycle activation and subsequent cell loss using retinoic acid differentiated human SH-SY5Y neuroblastoma cells as model system. In line with previous literature, we showed that in vitro preparations of soluble Aβ42 oligomers triggered cell cycle activation but not cell proliferation. As a new finding, we showed that Farnesylthiosalicylic acid (FTS), a specific chemical Ras inhibitor, prevented soluble Aβ42 oligomer preparation-induced cell cycle activation. Moreover, we showed that the expression of dominant negative mutant H-Ras (S17N) prevented soluble Aβ42 oligomer preparation-induced cell cycle activation, confirming the specific role of Ras in this pathway. As a possible better mimic of the situation in the AD brain, we prepared soluble oligomers from Aβ42 : Aβ40 (3:7) peptide mixture and showed that this oligomer preparation similarly induced cell cycle activation which was also inhibited by the Ras inhibitor. Finally, we showed that FTS prevented soluble Aβ42 oligomer preparationinduced cell death in our retinoic acid differentiated SH-SY5Y cells. Overall, our results strongly suggest that Ras activity is required for soluble Aβ oligomer-induced aberrant neuronal cell cycle reentry and subsequent neuronal loss, which are considered important mechanisms in AD pathogenesis.
authors.affiliation: Department of Genetics and Bioengineering, Fatih University, Istanbul, Turkey 34400.
authors.forename: M Murat
authors.initials: MM
authors.lastname: Koseoglu
authors.forename: Bagdeser Akdogan
authors.initials: BA
authors.lastname: Ozdilek
authors.forename: Umidahan
authors.initials: U
authors.lastname: Djakbarova
authors.forename: Ayse
authors.initials: A
authors.lastname: Gulusur
mesh_terms: D016229:Amyloid beta-Peptides / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects*; D016923:Cell Death / Q000187:drug effects*; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005204:Farnesol / Q000031:analogs & derivatives* / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D008869:Microtubule-Associated Proteins / Q000378:metabolism; D009447:Neuroblastoma / Q000473:pathology; D009474:Neurons / Q000187:drug effects; D010446:Peptide Fragments / Q000494:pharmacology*; D012459:Salicylates / Q000494:pharmacology*; D013997:Time Factors; D018631:ras Proteins / Q000378:metabolism*
chemical_list: D016229:Amyloid beta-Peptides; D004791:Enzyme Inhibitors; C489788:MAP2 protein, human; D008869:Microtubule-Associated Proteins; D010446:Peptide Fragments; D012459:Salicylates; C075222:amyloid beta-protein (1-42); C093323:farnesylthiosalicylic acid; D005204:Farnesol; D018631:ras Proteins